Clinical trials: Hemostatic Agents
Covid19
Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation strategy = low-dose low-molecular…
- Trial name
- HERO-19 (NCT04542408)
- Testing
- Anticoagulation Agents (Edoxaban and/or high dose LMWH)
- Where
- 10 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Purpura, Schoenlein-Henoch, Graft Versus Host Disease
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
OBJECTIVES: I. Determine whether there is prompt engraftment after autologous peripheral blood stem cell transplantation using filgrastim (G-CSF) mobilization in patients with life threatening autoimmune diseases. II.
- Conditions
- Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis
- Trial name
- NCT00006055
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Fairview University Medical Center
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma.
- Trial name
- BVRD (NCT01484626)
- Testing
- Bendamustine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loyola University
Multiple Myeloma, Refractory Multiple Myeloma
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Trial name
- NCT06348108
- Testing
- Talquetamab, Iberdomide, Dexamethasone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Alfred Chung, MD
Collagen Degeneration, Wrinkle
The Effects of Almond on Facial Skin Collagen and Wrinkles
Investigate the effects of almond consumption on collagen production, elastin levels, wrinkles, and pigmentation among premenopausal women and postmenopausal women belonging to all Fitzpatrick skin types.
- Conditions
- Collagen Degeneration, Wrinkle, Pigmentation, Elastic Skin
- Trial name
- NCT06074276
- Testing
- Food: whole almonds, Food: non-nut snack
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Multiple Myeloma
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Assessment of the antitumour effect of zoledronic acid in patients with multiple myeloma and asymptomatic biochemical relapse It´s proposed to investigate the use of Zoledronic acid as single therapy in patients with Multiple…
- Trial name
- AZABACHE (NCT01087008)
- Testing
- zoledronic acid, No treatment control
- Where
- 16 sites in Spain
- Volunteers
- 103 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Myeloma, Plasma-Cell
Phase I/II Study of hLL1 in Multiple Myeloma
This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.
- Conditions
- Multiple Myeloma, Myeloma, Plasma-Cell, PLASMACYTOMA
- Trial name
- NCT00421525
- Testing
- milatuzumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar…
- Trial name
- NCT00366106
- Testing
- bortezomib, dexamethasone, doxorubicin HCl liposome
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Accelerated Community Oncology Research Network
Waldenstrom's Macroglobulinemia
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Rituximab is a monoclonal antibody with proven efficacy in WM but responses are slow. Bortezomib has shown significant and rapid activity in WM.
- Trial name
- NCT01046006
- Testing
- Bortezomib, Rituximab, Dexamethasone
- Where
- 4 sites in Greece, Netherlands and 1 more
- Volunteers
- 59 people
- Sponsor
- Meletios A. Dimopoulos
Multiple Myeloma
Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The objective of this study is to evaluate the efficacy and safety of Velcade plus dexamethasone used as induction chemotherapy prior to autologous transplantation.
- Trial name
- NCT00337506
- Testing
- Dexamethasone, velcade
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma
This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely.
- Trial name
- NCT00547404
- Testing
- P276-00
- Volunteers
- 35 people
- Sponsor
- Piramal Enterprises Limited
Lymphoproliferative Disorder, Multiple Myeloma
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
This clinical trial evaluates the impact of preexisting and therapy-emergent germline and somatic variants on cytopenia in patients with multiple myeloma or CD19 positive lymphoproliferative disorder (LPD) following chimeric…
- Trial name
- NCT06630104
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Electronic Health Record Review
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- Mayo Clinic
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma.
- Trial name
- NCT02086552
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Sonidegib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Coagulopathy
A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients
The purpose of this study is to evaluate the clinical utility of thrombelastography (TEG) to predict and identify trauma patients at increased risk of receiving blood transfusion, develop multiple organ failure and mortality.
- Trial name
- RapidTEG (NCT01228058)
- Testing
- RapidTEG test
- Where
- 3 sites in United States
- Volunteers
- 1,450 people
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Myeloma
Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
The primary objective of this study is to evaluate the anti-tumor efficacy of tadalafil in combination with Lenalidomide/dexamethasone (Rd) in multiple myeloma.
- Trial name
- NCT01374217
- Testing
- Tadalafil, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Hodgkin's Lymphoma, Hodgkin Disease
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
The proposed study is based on our observation of paradoxical tumor regression after rejection of the donor graft in conjunction with the results of our murine experiments.
- Conditions
- Non Hodgkin's Lymphoma, Hodgkin Disease, Multiple Myeloma
- Trial name
- RLI (NCT00909948)
- Testing
- Fludarabine and total body irradiation, Total body irradiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research
The purpose of this study is to collect a blood or bone marrow sample from patients with multiple myeloma and from volunteers without myeloma.
- Trial name
- NCT01382615
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Multiple Myeloma
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a…
- Trial name
- NCT02332850
- Testing
- Isatuximab, Carfilzomib, Dexamethasone
- Where
- 6 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- Thomas Martin, MD
Cavernous Malformation, Cerebral, Cavernous Angioma
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate…
- Conditions
- Cavernous Malformation, Cerebral, Cavernous Angioma, Cavernous Hemangioma, Cavernous Hemangioma of Brain
- Trial name
- CRESS (NCT04076449)
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- yuanli Zhao
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.